Status:
ACTIVE_NOT_RECRUITING
Targeting Drug Memories With Methylphenidate
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Substance Use Disorder
Cocaine Use Disorder
Eligibility:
All Genders
26-50 years
Phase:
EARLY_PHASE1
Brief Summary
This study aims to identify the neural, behavioral, and pharmacological mechanisms promoting diminished expression of drug-related memories in human drug addiction. In this fMRI study with a within-su...
Detailed Description
Cue-exposure therapy has not proven efficacious in reducing relapse in drug addiction, illuminating the need for alternative strategies. Here researchers will test the neural correlates of two strateg...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Ability to understand and give informed consent
- Males and females, 18-65 years of age
- DSM-V diagnosis for CUD or otherwise problematic cocaine use as clinically determined
- Exclusion criteria:
- DSM-5 diagnosis for schizophrenia or developmental disorder (e.g., autism)
- Head trauma with loss of consciousness
- History of neurological disease of central origin including seizures
- Cardiovascular disease including high blood pressure and/or other medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, and infectious diseases including Hepatitis B and C or HIV/AIDS
- Metal implants or other MR contraindications
Exclusion
Key Trial Info
Start Date :
July 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 3 2026
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT05978167
Start Date
July 5 2023
End Date
September 3 2026
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029